In this health video learn how while most of the 22,000 women who are diagnosed with ovarian cancer each year respond to treatment, many of their cancers will return. A new therapy is helping keep that cancer away for good.
Read the full transcript »

Jennifer Matthews: Julie Lee's three new puppies are sure to bring a smile to her face. Julie Lee: They're such a joy. They're so fun!. Jennifer Matthews: She's needed the good times after being diagnosed with stage four ovarian cancer. Julie Lee: My first thought was, Oh my God, I have ovarian cancer. That's like one of the worst cancers you can possibly have. Jennifer Matthews: After chemotherapy and radiation, Julie went into remission. Good news, but Dr. Robert Holloway says 75% of patients in remission have their cancer return. Robert Holloway: Some of the most intense areas of research right now are to try and figure out how to take women who are in remission and keep them there. Jennifer Matthews: Now, researchers are studying a new therapy that may do just that. Catumaxomab or CAT for short is infused right into the abdomen through a port. It links immune cells to cancer cells. The body then creates an immune response to seek out and destroy the cancer cells. Robert Holloway: I can say in the patients that I treated, we have seen the immune response. Jennifer Matthews: Patients are given four injections over a month. Doctors have treated about 36 patients in a clinical trial. It's still early, but so far, all the women have remained in remission. Julie has the injections and has been in remission for nine months. Julie Lee: I hope that this clinical trial prevents me from ever having a relapse again, and I'll stay in remission forever. Jennifer Matthews: She says she wants to enjoy each and every moment with her little pups. This is Jennifer Matthews reporting.

Advertisement
Advertisement
Advertisement